A lot of smart people think so. The company, INmuneBio (INMB on NASDAQ), has three promising therapeutic platforms that are now ready for clinical trial. Two of these target Cancer, the other Alzheimer’s.All three are designed to reprogram the body’s immune system to allow it to fight these dread diseases. And...
Editor's Note: This article was updated on Mar 14, 2019 at 11:49 PM PKTAmid a report that it will seek an $800 million IPO, BioNTech told BioCentury it is still evaluating all financial options.Citing undisclosed people familiar with the IPO, Reuters has reported that BioNTech AG (Mainz, Germany) retained...
In the latest move by the scientific community to clamp down on rogue germline gene editing, a group of prominent scientists and ethicists is calling for a global moratorium on clinical uses of the technique and proposes it should remain in place until an international framework sets conditions under...
The smart money seems to think so. San Diego-based clinical-stage biotechnology company INmune Bio (NASDAQ:INMB) has three promising therapies now in clinical trial. Two of these target cancers; the other Alzheimer’s.All three of the company’s therapies are designed to reprogram the body’s immune system to help it defeat these diseases....
The scientific team behind drug delivery company Lyndra Therapeutics described a delivery device capable of releasing large payloads into the stomach over several weeks in a paper published in Science Translational Medicine on Wednesday. While the device is designed to improve compliance for long-term, frequently dosed treatment regimens, such...
Hercules Capital said Manuel Henriquez stepped down as chairman and CEO. Henriquez and his wife were charged Tuesday as part of a wide-ranging college admissions cheating scheme. The firm's board elected Robert Badavas, lead independent director at Hercules, as interim chairman, and Chief Investment Officer Scott Bluestein as interim...
China's National Medical Insurance Administration released its plan for issuing a revised National Drug Reimbursement List Wednesday, describing which types of drugs will have priority for inclusion and sketching out a timeline for a revision process that will run through August.While the revision will include both drugs and traditional...
Editor's Note: This article was updated on Mar 15, 2019 at 1:14 AM PKTDays after revealing the first clinical data from its gene therapy pipeline, Axovant raised $40 million through the sale of 26.7 million shares at $1.50 in a follow-on offering.Axovant Sciences Ltd. (NASDAQ:AXGT) proposed the offering after...
Mammoth exclusively licensed IP covering one of the newest families of CRISPR enzymes, Cas14, from the University of California Berkeley. The new license adds a third group of CRISPR enzymes to the diagnostics company's toolbox.While the IP landscape covering CRISPR-Cas9 for therapeutic applications is becoming increasingly complex following the...
Regenerative medicine company Surrozen raised a $50 Million series B round to move its optimized Wnt signaling mimetics into IND-enabling studies for an advanced liver disease yet to be determined.Surrozen Inc. (South San Francisco, Calif.) raised $33 million in a series A in 2017 led by The Column Group,...